NCT05249452View on ClinicalTrials.gov

Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2024

Conditions
Sickle Cell Disease
Interventions
OTHER

Preconditioning with azathiprine and hydroxyurea (3 months)

Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.

Trial Locations (1)

Unknown

Amsterdam Medical Centre, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT05249452 - Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients | Biotech Hunter | Biotech Hunter